繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

LifeWallet披露最新药品反垄断案中310万美元和解

2024-08-19 14:36

  • Company also announces a drive to secure agreements with health plans, property & casualty insurers, attorneys, and healthcare providers, including hospital systems
  • This subscription licensing is expected to generate revenue through fees charged on savings from unnecessary Medicare secondary payments
  • This is all part of LifeWallet's clearinghouse system, through its exclusive healthcare partnership with Palantir Technologies, Inc.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。